Jörg Kaufmann

This inventor holds 33 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in RNA Therapeutics. Top assignees: Silence Therapeutics Gmbh, Silence Therapeutics Aktiengesellschaft (Ag), Quark Pharmaceuticals, Inc.. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jörg Kaufmann. Retrieved from https://idiyas.com/inventor/jorg-kaufmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 10)

% Patents Active = 30.3

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 16)

Average Co-Inventor Count = 2.8

ph-index = 10

Forward Citations = 608(Granted Patents)

Company Filing History:

20 out of 38

Silence Therapeutics Gmbh

patents

5 out of 5

Silence Therapeutics Aktiengesellschaft (Ag)

patents

4 out of 67

Quark Pharmaceuticals, Inc.

patents

4. 4 out of 5

Silence Therapeutics Ag

patents

5. 1 out of 1

Pantherna Therapeutics Gmbh

patent

6. 1 out of 1

Silence Therpeutics Ag

patent

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Recombinant Nucleic Acid

Interfering RNA

Lipid Complexes

Protein Kinase Inhibitors

ANG2 Expression

RTP801 Inhibitors

Diabetic Eye Treatments

Oncogene Inhibition

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516348 - RECOMBINANT NUCLEIC ACID CONSTRUCT (2026-01-06),

2. 11578328 - Interfering RNA molecules (2023-02-14),

3. 10774332 - Interfering RNA molecules (2020-09-15),

4. 10329568 - Interfering RNA molecules (2019-06-25),

5. 10323246 - Interfering RNA molecules (2019-06-18),

6. 10266829 - Interfering RNA molecules (2019-04-23),

7. 9790505 - Interfering RNA molecules (2017-10-17),

8. 9790501 - Interfering RNA molecules (2017-10-17),

9. 9783802 - Interfering RNA molecules (2017-10-10),

10. 9758784 - Interfering RNA molecules (2017-09-12),

11. 9695423 - Interfering RNA molecules (2017-07-04),

12. 9486538 - Lipids, lipid complexes and use thereof (2016-11-08),

13. 9458461 - Means for inhibiting the expression of ANG2 (2016-10-04),

14. 9387262 - Coated lipid complexes and their use (2016-07-12),

15. 9222092 - Interfering RNA molecules (2015-12-29),

Title: Innovations and Contributions of Jörg Kaufmann in RNA Technology

Introduction

Jörg Kaufmann, based in Berlin, Germany, is a prolific inventor with a remarkable portfolio of 24 patents. His work is primarily focused on the advancements in ribonucleic acid (RNA) technology, which holds significant implications in the field of molecular biology and therapeutics.

Latest Patents

Among his latest patents are innovations related to interfering RNA molecules. These inventions involve ribonucleic acid structures that feature a double-stranded configuration. The first strand of Kaufmann's designs contains a sequence of contiguous nucleotides that is at least partially complementary to a target nucleic acid. Simultaneously, the second strand reflects a stretch of contiguous nucleotides that are at least partially identical to the target. These double-stranded structures are explicitly designed to be blunt-ended, showcasing an advanced understanding of RNA design and functionality.

Career Highlights

Throughout his career, Jörg Kaufmann has been associated with notable companies in the biotechnology sector, including Silence Therapeutics GmbH and Silence Therapeutics Aktiengesellschaft. His contributions have been instrumental in pushing the boundaries of RNA-based therapies, impacting research and development in genetic regulation.

Collaborations

Kaufmann has worked alongside esteemed colleagues, including Anke Klippel-Giese and Klaus Giese. These collaborations have fostered innovation and growth in his projects, amplifying the effectiveness and reach of his contributions to RNA technology.

Conclusion

Jörg Kaufmann’s inventive spirit and significant number of patents reflect his dedication to advancing RNA technology. His work not only enhances the scientific community's understanding of molecular biology but also paves the way for novel therapeutic approaches, showcasing the vital role of inventors in shaping the future of medicine.

Profile summary based on public USPTO records.